COVID-19 vaccines

Pfizer’s COVID-19 vaccine trial data shows long-term efficacy in adolescents

Nov 23, 2021 8:16 AM PHT

Reuters

SUMMARY

This is AI generated summarization, which may have errors. For context, always refer to the full article.

Pfizer’s COVID-19 vaccine trial data shows long-term efficacy in adolescents

VACCINE. Pfizer/BioNTech's new pediatric COVID-19 vaccine vials are seen in this undated handout photo.

Pfizer/Handout via Reuters

Pfizer and BioNTech will seek clearance for a 30-microgram dose of the vaccine for those aged 12 and above

Pfizer said on Monday, November 22, its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30-microgram dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August. – Rappler.com